Clinical benefits of pegylated proteins in oncology.
Publication
, Journal Article
Crawford, J
Published in: Cancer Treat Rev
April 2002
Duke Scholars
Published In
Cancer Treat Rev
DOI
ISSN
0305-7372
Publication Date
April 2002
Volume
28 Suppl A
Start / End Page
1 / 2
Location
Netherlands
Related Subject Headings
- Recombinant Proteins
- Proteins
- Polyethylene Glycols
- Oncology & Carcinogenesis
- Neoplasms
- Liposomes
- Interferon-alpha
- Interferon alpha-2
- Humans
- Granulocyte Colony-Stimulating Factor
Citation
APA
Chicago
ICMJE
MLA
NLM
Crawford, J. (2002). Clinical benefits of pegylated proteins in oncology. Cancer Treat Rev, 28 Suppl A, 1–2. https://doi.org/10.1016/s0305-7372(02)80001-9
Crawford, J. “Clinical benefits of pegylated proteins in oncology.” Cancer Treat Rev 28 Suppl A (April 2002): 1–2. https://doi.org/10.1016/s0305-7372(02)80001-9.
Crawford J. Clinical benefits of pegylated proteins in oncology. Cancer Treat Rev. 2002 Apr;28 Suppl A:1–2.
Crawford, J. “Clinical benefits of pegylated proteins in oncology.” Cancer Treat Rev, vol. 28 Suppl A, Apr. 2002, pp. 1–2. Pubmed, doi:10.1016/s0305-7372(02)80001-9.
Crawford J. Clinical benefits of pegylated proteins in oncology. Cancer Treat Rev. 2002 Apr;28 Suppl A:1–2.
Published In
Cancer Treat Rev
DOI
ISSN
0305-7372
Publication Date
April 2002
Volume
28 Suppl A
Start / End Page
1 / 2
Location
Netherlands
Related Subject Headings
- Recombinant Proteins
- Proteins
- Polyethylene Glycols
- Oncology & Carcinogenesis
- Neoplasms
- Liposomes
- Interferon-alpha
- Interferon alpha-2
- Humans
- Granulocyte Colony-Stimulating Factor